{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:51:35Z","timestamp":1782978695507,"version":"3.54.5"},"reference-count":44,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Big data in drug development may not satisfactorily address the demands of precision medicine in a rare disease population, making the use of smaller clinical trials necessary. Consequently, the use of innovative design and analysis of these clinical trials using model\u2010informed approaches have become indispensable. This requires informative exposure\u2013outcome analysis, together with formal statistical analysis, which should include the strength of evidence for a study outcome. We demonstrate how knowledge can be gained, with supporting strength of evidence, from a small (data) clinical trial with a low dose of blarcamesine in the treatment of Rett syndrome. Based on a small data paradigm, pharmacometrics item response theory modelling and Bayes factor analysis were used to demonstrate the efficacy of blarcamesine in Rett syndrome.<\/jats:p>","DOI":"10.1111\/bcp.15843","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T01:04:11Z","timestamp":1689037451000},"page":"1049-1063","source":"Crossref","is-referenced-by-count":4,"title":["The new big is small: Leveraging knowledge from small trials for rare disease drug development: Blarcamesine for Rett syndrome"],"prefix":"10.1111","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3227-0454","authenticated-orcid":false,"given":"Ene I.","family":"Ette","sequence":"first","affiliation":[{"name":"Anoixis Corporation  Natick Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel O.","family":"Fadiran","sequence":"additional","affiliation":[{"name":"Anavex Life Sciences Corp.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Missling","sequence":"additional","affiliation":[{"name":"Anavex Life Sciences Corp.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Hammond","sequence":"additional","affiliation":[{"name":"Anavex Life Sciences Corp.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12896"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1196187"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1500523"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7023.71"},{"key":"e_1_2_11_6_1","unstructured":"Improving Outcomes through Personalised Medicine.Working at the cutting edge of science to improve patients' lives.2016. Accessed 15 Dec 2022.https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2016\/09\/improving-outcomes-personalised-medicine.pdf"},{"key":"e_1_2_11_7_1","unstructured":"The Precision Medicine Advisory Committee.Precision Medicine: An Action Plan for California.2018. Accessed 15 Dec 2022.http:\/\/opr.ca.gov\/docs\/20190107-Precision_Medicine_An_Action_Plan_for_California.pdf"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1145\/2580944"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9787.2009.00641.x"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rceng.2013.09.002"},{"key":"e_1_2_11_11_1","unstructured":"BrooksD.The philosophy of data. New York Times 4 Feb.2013."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f167"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1401111"},{"key":"e_1_2_11_14_1","first-page":"713","article-title":"Randomized database studies: a new method to assess drugs' effectiveness?","volume":"51","author":"Sacristan JA","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1310102"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e55"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta18430"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.5914"},{"key":"e_1_2_11_19_1","volume-title":"The black swan: the impact of the highly improbable","author":"Taleb NN","year":"2007"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.202.11.1028"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573\u2010019\u201000180\u2010y"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02299-5"},{"key":"e_1_2_11_23_1","unstructured":"New Report Shows 28% Increase in YoY Funding for Rare Disease Drug Development in 2021. 01\/13\/2022. Accessed Dec 19 2022.https:\/\/www.businesswire.com\/news\/home\/20220112005794\/en\/New-Report-Shows-28-Increase-in-YoY-Funding-for-Rare-Disease-Drug-Development-in-2021"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02048-0"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197\u20102456(90)90003\u2010K"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804385"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv193"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2006.10.003"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.10.037"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22124"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/13810"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-7610.00236"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2020.01.009"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2014.00463"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2019.172796"},{"key":"e_1_2_11_37_1","article-title":"ANAVEX 2\u201373as a potential treatment of Rett syndrome and other pediatric or infantile disorders with seizure pathology","author":"Rebowe N","year":"2016","journal-title":"Rett Syndrome Symposium"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.07.001"},{"key":"e_1_2_11_39_1","unstructured":"NCT03758924.Study of ANAVEX2\u201373 in patients with Rett Syndrome. [Protocol ANAVEX2\u201373\u2010RS\u2010001]: a double\u2010blind randomized placebo\u2010controlled dose titration study of ANAVEX2\u201373 in patients with Rett syndrome version 7.2. Dated June 10 2020."},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2409"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1570"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/acprof:oso\/9780195377033.001.0001"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110379286"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12013"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326\u20105377.2004.tb05928.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T09:42:53Z","timestamp":1744450973000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/bcp.15843"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15843","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,3]]}}}